Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Fructosediphosphates”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,351 records · Page 75Linked to original sources

Activation of muscle phosphofructokinase by fructose 2,6-bisphosphate and fructose 1,6-bisphosphate is differently affected by other regulatory metabolites.

Fructose-2,6-P2 and fructose-1,6-P2 are strong activators of muscle phosphofructokinase. They have been shown to be competitive in binding studies, and it is generally thought that they affect the physical and catalytic properties of the enzyme in the same manner. However, there are indications in published data that the effects of the two fructose bisphosphates on phosphofructokinase are not identical. To examine this possibility, the kinetics of activation of rat skeletal muscle phosphofructokinase by the two fructose bisphosphates were compared in the presence of other regulatory metabolites. Citrate greatly increased the K0.5 of the enzyme for fructose-2,6-P2, with little effect on the maximum activation. In contrast, citrate greatly decreased the maximum activation by fructose-1,6-P2, with only a small effect on the K0.5. Changes in the concentrations of the inhibitor ATP or the activator AMP similarly altered the K0.5 for fructose-2,6-P2, but altered the maximum activation by fructose-1,6-P2. Finally, when fructose-1,6-P2 was added in the presence of a given concentration of fructose-2,6-P2, phosphofructokinase activity was decreased if the activation by fructose-2,6-P2 alone was greater than the maximum activation by fructose-1,6-P2 alone. These results are consistent with competition of the two fructose bisphosphates for the same binding site, but indicate that the conformational changes produced by their binding are different.

Adenosine Monophosphate↗

Regulation of phosphofructokinase in perfused rat heart. Requirement for fructose 2,6-bisphosphate and a covalent modification.

Phosphofructokinase from rat heart perfused with epinephrine was purified to homogeneity and various allosteric properties were determined under conditions which approximate physiological concentrations of the substrates, effectors, and pH. The molecular weights of the protomer of the enzyme isolated from the hormone-stimulated and the control hearts are both approximately 83,000. The epinephrine-stimulated and the control enzymes contain 1.1 and 0.66 mol of phosphate/mol of protomer, respectively. Both enzymes can be fully phosphorylated by cAMP-dependent protein kinase indicating that the phosphorylation site is new and distinct from the known phosphorylation site of skeletal muscle phosphofructokinase. Pure phosphofructokinase isolated from the epinephrine-stimulated heart is significantly less sensitive to inhibition by ATP and citrate, and the K0.5 values for Fru-6-P (0.18 mM) and Fru-2,6-P2 (3 microM) are one-half those for the enzyme from control hearts. In the presence of in vivo concentrations of ATP, citrate, and Fru-6-P at pH 7.1, both enzymes are inactive in the absence of Fru-2,6-P2. Moreover, the K0.5 values for Fru-2,6-P2 of the hormone-stimulated and untreated enzymes are 3 and 6 microM, respectively. These differences in the allosteric properties of phosphofructokinases from the hormone-treated and the control hearts disappear when the enzymes are dephosphorylated by alkaline phosphatase. Determination of the glycolytic intermediates showed a 2-fold increase in Fru-6-P, Fru-2,6-P2, and AMP and 13-fold increase in Fru-1,6-P2. Partially purified Fru-6-P,2-kinase from epinephrine-stimulated and control hearts show KFru-6-P0.5 = 4 and 15 microM, respectively. These results indicate that rat heart phosphofructokinase in vivo requires Fru-2,6-P2 for its activity. Epinephrine stimulates phosphorylation of phosphofructokinase which results in a more active form. The hormone also increases Fru-2,6-P2 which appears to be the result of an activation of Fru-6-P,2-kinase by a covalent modification.

Animals↗

Fructose 2,6-bisphosphate and the control of glycolysis by glucocorticoids and by other agents in rat hepatoma cells.

The rate, key enzymes, and several metabolites of glycolysis in rat hepatoma (HTC) cells have been compared to those in rat hepatocytes. At 5 to 10 mM glucose, lactate release was greater in HTC cells. This could be explained in part by the absence of key gluconeogenic enzymes, by the substitution of glucokinase by hexokinase, and by an increase in phosphofructokinase 1 and pyruvate kinase activity. In addition, fructose 2,6-bisphosphate, the most potent stimulator of phosphofructokinase 1, was identified in HTC cells and shown to stimulate phosphofructokinase 1 partially purified from these cells. Dexamethasone increased the release of lactate in HTC cells. This glucocorticoid increased the concentration of fructose 2,6-bisphosphate and the Vmax of the enzyme that catalyzes its synthesis, phosphofructokinase 2. The data were consistent with an indirect effect at the gene level, mediated by glucocorticoid receptors. Dexamethasone had no effect on the other rate-limiting glycolytic enzymes. Several agents (adenosine, dibutyryl cyclic adenosine 3':5'-monophosphate, ethanol, antimycin) known to decrease fructose 2,6-bisphosphate in hepatocytes were without effect on this stimulator in HTC cells. DL-Glyceraldehyde inhibited glycolysis in HTC cells and eventually killed them. Although this substance decreased fructose 2,6-bisphosphate inhibition of glycolysis through an action at another level could not be ruled out.

Adenosine↗

Effects of fructose-1,6-diphosphate on heart rate, ventilation, oxygen consumption and endurance performance.

A controlled study was carried out in 12 healthy male volunteers to evaluate the effects of fructose-1,6-diphosphate (FDP) on cardiac and respiratory parameters and work capacity during maximal muscular exercise on a cycloergometer. Each subject was studied in 3 sessions, separated by at least 36 hours. Workload started at 50 watts with stepwise increases, consisting of 25 watts every 3 minutes, up to muscular exhaustion or until the predicted maximum heart rate was attained. The first session, with no treatment, served as the control test; in the other two sessions, each subject received, prior to exercising, a single intravenous dose of either 7.5 g dextrose or 15 g FDP, according to a within-subject comparative study design. In resting conditions and during the exercise, heart rate, ventilation (VE), and oxygen consumption (VO2) were monitored. At the end of each session, the total work (TW) performed and the maximum oxygen consumption (VO2 max) were computed. No difference was found between the values obtained in the control and dextrose treatment sessions. The increments in heart rate, VE and VO2 at each workload observed after FDP treatment were lower (p less than 0.01) than those in control and dextrose sessions. A 25% increase in TW associated with a 12% increase in VO2 max was observed after FDP (p less than 0.01). The data indicate that FDP is potentially capable of improving muscular performance, and several possible mechanisms of action for the observed effects are discussed.

Adult↗

Bass liver 6-phosphogluconate dehydrogenase: inhibition by nucleoside phosphates and by fructose 1,6 bisphosphate.

Nucleoside 5'-triphosphates, 5'-diphosphates and 5'-monophosphates are inhibitors of the 6-phosphogluconate dehydrogenase enzyme from bass liver. The 2'- and 3'-monophosphates of adenosine and guanosine are also inhibitory, the 2'-isomers being especially potent inhibitors. The catalytic activity of 6-phosphogluconate dehydrogenase has been found to be markedly inhibited by fructose 1, 6 bisphosphate. As the Km for 6-phosphogluconate, the Ki for fructose 1,6 bisphosphate and the concentration of both compounds in bass liver are all comparable, it appears that the inhibition of 6-phosphogluconate dehydrogenase by fructose 1,6 bisphosphate may be of significance in the regulation of carbohydrate metabolism in bass liver.

Animals↗

Metabolic regulation of glycolysis in sea bass (Dicentrarchus labrax L.) muscle. I. Kinetic study and characteristic modulators of pyruvate kinase.

White muscle pyruvate kinase from sea bass presents positive cooperativity with respect to PEP substrate. The enzyme is regulated by F-1.6-P2 and L-Phenylalanine. The activator effect of F-1.6-P2 in experiments carried out for the substrate PEP with crude extract seems to indicate that the enzyme is activated in vivo by this compound. The enzyme was not inhibited by either alanine or ATP but was inhibited by L-phenylalanine. Therefore this enzyme presents kinetic and regulatory properties similar to those of the mammalian isozyme M2.

Adenosine Diphosphate↗

Analysis of pH-induced changes of the glycolysis of human erythrocytes.

The full time courses of some important metabolites of the glycolysis of human erythrocytes are reported following pH-shifts from pH 7.4 to 8.1 and from 8.1 to 6.9. The regulatory enzymes which are affected by the pH-transitions have been identified by computer simulation using a mathematical model of the erythrocyte glycolysis. It is concluded that in the transition to pH 8.1 the hexokinase-phosphofructokinase system is activated and the pyruvate kinase is inhibited. At pH 6.9 the hexokinase-phosphofructokinase system and the bisphosphoglycerate mutase are inhibited whereas the non-glycolytic ATP-consuming processes seem to be activated.

Adenosine Diphosphate↗

Potentiation by glucose metabolites of inositol trisphosphate-induced calcium mobilization in permeabilized rat pancreatic islets.

Saponin-permeabilized rat pancreatic islets degraded exogenously added inositol 1,4,5-trisphosphate (IP3), and degradation was inhibited in the presence of either fructose 1,6-bisphosphate or diphosphoglycerate. The addition of either fructose-1,6-P2 or diphosphoglycerate to 45Ca2+-labeled permeabilized islets potentiated 45Ca2+ release caused by IP3 (by either exogenously added IP3 or IP3 generated endogenously in the presence of carbachol or guanosine 5'-3-O-(thio)triphosphate (GTP gamma S). The effect of diphosphoglycerate and fructose-1,6-P2 on 45Ca2+ release correlated well with the effects of these agents on the recovery of radioactivity in IP3. These results further support our previous proposal that in pancreatic islets intracellular calcium mobilization may be sustained in part via the inhibition of IP3 degradation by metabolites produced during stimulation with insulinotropic concentrations of glucose (Rana, R.S., Sekar, M.C., Hokin, L.E., and MacDonald, M.J. (1986) J. Biol. Chem. 261, 5237-5240).

Animals↗

Liver gluconeogenic metabolites in young and old rats during septic shock.

Aged individuals have diminished resistance to severe sepsis and septic shock. Previous studies in young animals showed that the liver's gluconeogenic capacity was an important determinant of survival in shock states. This study compared hepatic carbohydrate intermediates from young rats and old rats to correlate changes during peritonitis septic shock with known differences in survival times. Old control rats had glucose 6-phosphate (G6P) concentrations two-fold higher than young controls, 354 +/- 49 nanomole/g wet liver vs 180 +/- 41, suggesting a reduced ability to convert hexose monophosphate precursor into blood sugar. There was a 53% increase in G6P levels in the peritonitis livers, to 540 +/- 155 nanomole/g liver while in young septic rats the G6P decreased 33 per cent. These opposite, highly significant changes in shock (P = 0.01) show the reduced ability of old animals to mobilize gluconeogenic precursors. Fructose 1,6-biphosphate (FBP) in old control liver was 14 +/- 3 nanomole/g liver and did not change in shock; in young rats, FBP was 7.0 +/- 3 nanomole and increased 230 per cent in shock, showing a different metabolic response in young and old animals. These data suggest older animals may be more vulnerable to shock because of lower gluconeogenic potential.

Aging↗

Inability of fructose 1,6-diphosphate to reduce myocardial infarct size.

Fructose 1,6-diphosphate has been reported to reduce ischemic damage following coronary artery occlusion. To further evaluate fructose 1,6-diphosphate, we studied its effect on myocardial infarct size in open-chest, anesthetized dogs. Twenty min following left anterior descending coronary artery ligation, the animals received a constant infusion of either normal saline or fructose 1,6-diphosphate. Six hours following coronary artery ligation, the animals were killed and the hearts were sectioned from base to apex. Area at risk, infarct size, and infarct size expressed as a percentage of the area at risk were determined. Fructose 1,6-diphosphate had no effect on the amount of necrosis following coronary artery ligation. The area of necrosis expressed as a percentage of the left ventricle was similar in control (26 +/- 3%) and treated groups (24 +/- 4%). The area of necrosis expressed as a percentage of the area at risk was also similar in control and treated groups. Thus, in this model of myocardial ischemia, fructose 1,6-diphosphate does not reduce myocardial infarct size.

Animals↗

Phosphoethanolamine- and fructose 1,6-diphosphate-induced calcium uptake in bone formed in vitro.

The purpose of this investigation was to determine whether biologically available organic phosphates other than beta-glycerophosphate were capable of inducing mineralization of bone in vitro. The chick periosteal osteogenesis model was used to demonstrate that endogenously available organic phosphates, fructose 1,6-diphosphate (F1,6-D) and phosphoethanolamine (PEA) induce calcium accumulation in bone formed in vitro. Alkaline phosphatase activity was inhibited in a dose-dependent manner by PEA, and the sodium salt of F1,6-D. There was an inverse correlation between alkaline phosphatase activity and organic phosphate-mediated mineralization. The data demonstrate that certain biologically available organic phosphates can induce mineralization and modulate bone metabolism in vitro.

Alkaline Phosphatase↗

Regulation of fructose-2,6-bisphosphate and glycogen synthesis by dichloroacetate and phenazine methosulphate in rat adipose tissue.

The effects of dichloroacetate and phenazine methosulphate on the content of fructose-2,6-bisphosphate and glycogenesis in incubated epididymal adipose tissue were examined. Both agents stimulated the synthesis of fructose-2,6-bisphosphate in the presence of glucose, the effect being higher in tissue from fasted-refed rats than in normal fed rats. Additions of dichloroacetate to the incubation medium also increased the incorporation of [U-14C]glucose into glycogen and this effect was additive with that of insulin. However phenazine methosulphate strongly depressed the insulin-dependent glycogen synthesis. These data are considered in relation to the increased rate of glucose metabolism known to occur in the presence of dichloroacetate and the stimulation of pentose phosphate pathway with phenazine methosulphate.

Acetates↗